Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 197

1.

Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia.

Lambert BL, Cunningham FE, Miller DR, Dalack GW, Hur K.

Am J Epidemiol. 2006 Oct 1;164(7):672-81. Epub 2006 Aug 30.

PMID:
16943266
2.

Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.

Lambert BL, Chou CH, Chang KY, Tafesse E, Carson W.

Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):417-25.

PMID:
15786516
3.

Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.

Dossenbach M, Pecenak J, Szulc A, Irimia V, Anders M, Logozar-Perkovic D, Peciukaitiene D, Kotler M, Smulevich AB, West TM, Lowry AJ, Treuer T.

J Clin Psychiatry. 2008 Dec;69(12):1901-15. Epub 2008 Sep 9.

PMID:
19012820
4.

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.

Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R.

Am J Psychiatry. 2002 Apr;159(4):561-6.

PMID:
11925293
5.

Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.

Leslie DL, Rosenheck RA.

Am J Psychiatry. 2004 Sep;161(9):1709-11.

PMID:
15337666
6.

Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.

Dossenbach M, Erol A, el Mahfoud Kessaci M, Shaheen MO, Sunbol MM, Boland J, Hodge A, O'Halloran RA, Bitter I; IC-SOHO Study Group.

J Clin Psychiatry. 2004 Mar;65(3):312-21.

PMID:
15096069
7.

Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study.

Chatterjee S, Chen H, Johnson ML, Aparasu RR.

Am J Geriatr Pharmacother. 2012 Apr;10(2):83-94. doi: 10.1016/j.amjopharm.2011.10.006. Epub 2012 Feb 10.

PMID:
22306198
9.

Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.

Bobes J, Garc A-Portilla MP, Rejas J, Hern Ndez G, Garcia-Garcia M, Rico-Villademoros F, Porras A.

J Sex Marital Ther. 2003 Mar-Apr;29(2):125-47.

PMID:
12623765
10.

A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.

Newcomer JW, Ratner RE, Eriksson JW, Emsley R, Meulien D, Miller F, Leonova-Edlund J, Leong RW, Brecher M.

J Clin Psychiatry. 2009 Apr;70(4):487-99. Epub 2009 Apr 7.

11.

Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.

Mullins CD, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD.

Schizophr Res. 2008 Jan;98(1-3):8-15. Epub 2007 Jun 26.

PMID:
17596914
12.

Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia?

Rossom RC, Rector TS, Lederle FA, Dysken MW.

J Am Geriatr Soc. 2010 Jun;58(6):1027-34. doi: 10.1111/j.1532-5415.2010.02873.x. Epub 2010 May 7.

PMID:
20487081
13.

Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.

Bobes J, Rejas J, Garcia-Garcia M, Rico-Villademoros F, García-Portilla MP, Fernández I, Hernández G; EIRE Study Group.

Schizophr Res. 2003 Jul 1;62(1-2):77-88.

PMID:
12765747
14.

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.

Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK; CATIE Investigators.

Am J Psychiatry. 2007 Mar;164(3):415-27.

PMID:
17329466
15.

Cost of antipsychotic polypharmacy in the treatment of schizophrenia.

Zhu B, Ascher-Svanum H, Faries DE, Correll CU, Kane JM.

BMC Psychiatry. 2008 Apr 4;8:19. doi: 10.1186/1471-244X-8-19.

16.

Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States.

Feldman PD, Hay LK, Deberdt W, Kennedy JS, Hutchins DS, Hay DP, Hardy TA, Hoffmann VP, Hornbuckle K, Breier A.

J Am Med Dir Assoc. 2004 Jan-Feb;5(1):38-46.

PMID:
14706127
17.

Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.

Garman PM, Ried LD, Bengtson MA, Hsu C, McConkey JR.

J Am Pharm Assoc (2003). 2007 May-Jun;47(3):373-8.

PMID:
17510032
18.

Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.

Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, Kales HC.

JAMA Psychiatry. 2015 May;72(5):438-45. doi: 10.1001/jamapsychiatry.2014.3018.

19.

How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.

Suzuki T, Uchida H, Watanabe K, Nomura K, Takeuchi H, Tomita M, Tsunoda K, Nio S, Den R, Manki H, Tanabe A, Yagi G, Kashima H.

Psychopharmacology (Berl). 2007 Dec;195(2):285-95. Epub 2007 Aug 14.

PMID:
17701027
20.

A real-world data analysis of dose effect of second-generation antipsychotic therapy on hemoglobin A1C level.

Guo Z, L'italien GJ, Jing Y, Baker RA, Forbes RA, Hebden T, Kim E.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jul 1;35(5):1326-32. doi: 10.1016/j.pnpbp.2011.03.020. Epub 2011 Apr 15.

PMID:
21515328

Supplemental Content

Support Center